FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma

Season 5 Episode 5  ·  May 06, 2021, 08:20 PM

Headliner
Share
Subscribe

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Share
Subscribe
Next
Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air